文献速递区域麻醉与超声疼痛医学

右美托咪定加重糖尿病大鼠罗哌卡因坐骨神经损伤

Dexmedetomidine enhances ropivacaine-induced sciatic nerve injury in diabetic rats.
PubMed 文献 · Br J Anaesth · 2018-10-04

在链脲佐菌素诱导的糖尿病大鼠中,坐骨神经周围注射0.5%罗哌卡因可致显著神经纤维损伤,而联合20 μg kg-1右美托咪定后损伤进一步加重,表现为运动神经传导速度减慢、轴突密度降低及G比率下降,并伴白细胞介素-1β和肿瘤坏死因子-α升高。非糖尿病对照大鼠中未见神经纤维损伤。

要点

  • 糖尿病大鼠中0.5%罗哌卡因可致坐骨神经损伤,右美托咪定加重该损伤
  • 损伤表现为MNCV减慢、轴突密度降低、G比率下降及脱髓鞘
  • 非糖尿病大鼠中罗哌卡因和/或右美托咪定未致神经纤维损伤

核心结论

  • 0.5%罗哌卡因在糖尿病大鼠中引起显著坐骨神经损伤,高剂量右美托咪定大幅增强该损伤。

研究设计与样本

  • 成年雄性Sprague-Dawley大鼠腹腔注射链脲佐菌素建立糖尿病状态,对照组和糖尿病组每组n=8,坐骨神经周围注射0.5%罗哌卡因、20 μg kg-1右美托咪定(单用及联用)或生理盐水(均0.2 ml)。

主要发现

  • 对照非糖尿病大鼠中,罗哌卡因和右美托咪定单用或联用均未产生神经纤维损伤。
  • 糖尿病大鼠中,罗哌卡因诱导显著神经纤维损伤,右美托咪定增强该损伤。
  • 损伤表现为MNCV减慢、轴突密度降低、髓鞘内/外径比(G比率)下降,电镜见脱髓鞘、轴突消失和空泡。
  • 伴神经白细胞介素-1β和肿瘤坏死因子-α升高。

临床怎么用

  • 提示糖尿病患者外周神经阻滞中罗哌卡因与右美托咪定联用的安全性需进一步研究,但本研究右美托咪定剂量远高于临床常用剂量。

局限性

  • 本研究所用右美托咪定剂量显著高于临床实践剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies suggest that dexmedetomidine has a protective effect against local anaesthetic-induced nerve injury in regional nerve blocks. Whether this potentially protective effect exists in the context of diabetes mellitus is unknown. METHODS: A diabetic state was established in adult male Sprague-Dawley rats with intraperitoneal injection of streptozotocin. Injections of ropivacaine 0.5%, dexmedetomidine 20 μg kg-1 (alone and in combination), or normal saline (all in 0.2 ml) were made around the sciatic nerve in control and diabetic rats (n=8 per group). The duration of sensory and motor nerve block and the motor nerve conduction velocity (MNCV) were determined. Sciatic nerves were harvested at post-injection day 7 and assessed with light and electron microscopy or used for pro-inflammatory cytokine measurements. RESULTS: Ropivacaine and dexmedetomidine alone or in combination did not produce nerve fibre damage in control non-diabetic rats. In diabetic rats, ropivacaine induced significant nerve fibre damage, which was enhanced by dexmedetomidine. This manifested with slowed MNCV, decreased axon density, and decreased ratio of inner to outer diameter of the myelin sheath (G ratio). Demyelination, axon disappearance, and empty vacuoles were also found using electron microscopy. An associated increase in nerve interleukin-1β and tumour necrosis factor-α was also seen. CONCLUSIONS: Ropivacaine 0.5% causes significant sciatic nerve injury in diabetic rats that is greatly potentiated by high-dose dexmedetomidine. Although the dose of dexmedetomidine used in this study is considerably higher than that used in clinical practice, our data suggest that further studies to assess ropivacaine (alone and in combination with dexmedetomidine) use for peripheral nerve blockade in diabetic patients are warranted.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Yu ZY, Geng J, Li ZQ, et al. Dexmedetomidine enhances ropivacaine-induced sciatic nerve injury in diabetic rats. Br J Anaesth. 2018. PMID: 30579393. doi:10.1016/j.bja.2018.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。